QNCX Stock Summary and Trading Ideas (Quince Therapeutics | NASDAQ:QNCX)

Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

Quince Therapeutics trades on the NASDAQ stock market under the symbol QNCX.

As of September 11, 2026, QNCX stock price climbed to $29.16 with 7,041 million shares trading.

QNCX has a beta of 2.36, meaning it tends to be more sensitive to market movements. QNCX has a correlation of 0.01 to the broad based SPY ETF.

QNCX has a market cap of $29.66 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, QNCX traded as high as $909.98 and as low as $15.10.

The top ETF exchange traded funds that QNCX belongs to (by Net Assets): VXF.

QNCX has underperformed the market in the last year with a price return of -90.9% while the SPY ETF gained +18.6%. However, in the short term, QNCX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +60.2% vs +5.9% return in SPY. But in the last 2 weeks, QNCX shares have been beat by the market, returning -10.3% compared to an SPY return of -0.7%.

QNCX support price is $27.38 and resistance is $30.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QNCX shares will trade within this expected range on the day.